My watch list  

BioVex is a Phase II clinical-stage biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Our pipeline of cancer product candidates is built on first-in-class oncolytic virus technology that replicates and spreads within solid tumors, causing the death of cancer cells, accompanied by the induction of a systemic immune response.

More about BioVex
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE